| IPTp-SP | ISTp-AL | |
---|---|---|---|
Costs per 1000 pregnant women | Health provider excluding consequencesb (US$ 2012) | 1631.84 (1100.11–2316.97) | 5778.77 (4701.65–7039.15)a |
Health provider including consequencesb (US$ 2012) | 9006.54 (5610.30–13,680.56) | 13,972.79 (10,199.65–18,983.86)a | |
Measurable outcomes contributing to DALYs per 1000 women [20] | LBW | 151 (137–167) | 156 (141–172) |
severe/moderate anaemia | 17 (12–25) | 23 (17–32) | |
clinical malaria (total episodes)c | 74 (61–92) | 115 (96–144) | |
Other measurable outcomes per 1000 women and side effects [20, 37] | Placental malaria: active infection (acute and chronic) | 245 (224–265) | 242 (222–262) |
Dizziness | 46 (38–54) | 25 (19–31) | |
Sleeplessness | 13 (9–17) | 7 (4–10) | |
Weakness | 30 (24–37) | 18 (13–23) | |
Nausea | 22 (16–28) | 13 (9–17) | |
Vomiting | 45 (37–53) | 26 (20–32) | |
Non measurable outcomes | Intrinsic value of giving less drugs to pregnant women | ||
Value to individual of knowing about positive test | |||
Value of knowing about positive test for surveillance | |||
Deprivation of treatment for false negatives |